Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) EBIT Margin (2020 - 2023)

Candel Therapeutics' EBIT Margin history spans 4 years, with the latest figure at 1533.14% for Q4 2023.

  • For Q4 2023, EBIT Margin rose 2766862.0% year-over-year to 1533.14%; the TTM value through Dec 2023 reached 1479.42%, up 2948103.0%, while the annual FY2024 figure was 1596.7%, 307612.0% down from the prior year.
  • EBIT Margin for Q4 2023 was 1533.14% at Candel Therapeutics, up from 1324.51% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1581.77% in Q1 2023 and bottomed at 128983.33% in Q4 2021.
  • The 4-year median for EBIT Margin is 19758.06% (2020), against an average of 24064.89%.
  • The largest annual shift saw EBIT Margin plummeted -10922527bps in 2021 before it surged 10284785bps in 2022.
  • A 4-year view of EBIT Margin shows it stood at 19758.06% in 2020, then plummeted by -553bps to 128983.33% in 2021, then soared by 80bps to 26135.48% in 2022, then surged by 106bps to 1533.14% in 2023.
  • Per Business Quant, the three most recent readings for CADL's EBIT Margin are 1533.14% (Q4 2023), 1324.51% (Q3 2023), and 1487.42% (Q2 2023).